Study of orca-t for leukemia or MDS with reduced intensity chemo
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have acute myeloid leukemia, mixed phenotype leukemia (in remission or nearly so), or certain types of MDS with low blast counts.
- You will receive a reduced-intensity or nonmyeloablative preparative regimen (chemo and low-dose radiation).
- You have a related or unrelated donor who is an 8/8 HLA match.
- Your heart, lungs, and kidneys work well enough, and your liver function is within limits.
- You have not had a prior stem cell transplant and are not on high-dose steroids or immunotherapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
This program offers the experimental cell therapy Orca-T to people with advanced blood cancers when the standard approved version isn't available due to manufacturing or timing issues. It provides a possible treatment option when remaking the therapy isn't an option.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial tests a stronger chemotherapy and radiation regimen before a donor stem cell transplant for people with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to eliminate any remaining cancer cells and improve transplant success.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Hear when a new Leukemia, Myeloid, Acute trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.